Is Eli Lilly (LLY) a Buy Right Now?
A plain-English read on Eli Lilly stock — what the chart and the numbers are saying today, with no jargon and no hype.
What this means, in plain English
Eli Lilly is currently trading at $1185.71, showing a slight daily dip of 0.52%. The price sits above the 200-day average of $1051.09, which suggests a steady long-term upward trend. Investors often look for this pattern to confirm a company is moving in a positive direction over time.
The RSI, or Relative Strength Index—a gauge of whether a stock has climbed too far, too fast—sits at 54.4. This neutral reading indicates the stock is neither overbought nor oversold. With the current price above the 50-day average of $1168.36, the momentum remains supportive of our buy decision.
Should you buy Eli Lilly stock?
The data supports a buy rating because the price maintains a consistent trend above its long-term averages. While the market fluctuates, the current position relative to the $1109.15 support floor provides a reasonable entry point for those building a portfolio.
Is LLY a good stock for beginners?
Eli Lilly is a large, established company, which can offer more stability than smaller, speculative firms. However, even large stocks experience volatility, as seen by the 52-week range of $712.05 to $1249.45, so beginners should always focus on long-term holding rather than short-term price swings.
What's driving LLY right now
The stock price is currently above its 200-day average of $1051.09, signaling a positive long-term direction.
The recent support level of $1109.15 provides a clear baseline for the stock's current valuation.
The RSI of 54.4 confirms the stock is currently moving at a balanced, sustainable pace.
A P/E ratio of 25.5 means you are paying a premium for current earnings, which is common for large companies.
What Eli Lilly actually does
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; and BioArctic AB (publ) for new treatment. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Who owns Eli Lilly?
Institutions — pension funds, asset managers, index providers — hold 85.4% of LLY, and the concentration matters: the largest single holder alone controls 9.60% of the company.
| Holder | Shares | % held |
|---|---|---|
| 90.38M | 9.60% | |
| 66.38M | 7.05% | |
| 53.36M | 5.67% |
Names withheld — plus 3 more records not shown.
See who owns itWhat Eli Lilly insiders have been doing
Executives and directors must disclose their own trades in company stock. Of the last 6 disclosed transactions we hold for Eli Lilly, none were an open-market buy or sell — they are awards, vesting, option exercises or derivative conversions, which is normal and says nothing about conviction either way. Insiders sell for many ordinary reasons — scheduled plans, tax, diversification — so a sale is not by itself a signal.
| Insider | Date | Type | Shares | Value |
|---|---|---|---|---|
| 2026-07-31 | AWARD / VEST | 981 | — | |
| 2026-07-20 | AWARD / VEST | 4 | $5.0K | |
| 2026-07-20 | AWARD / VEST | 10 | $12.4K |
Names withheld — plus 3 more records not shown.
See which insidersThe numbers behind the read
Who in Washington has been trading LLY?
Members of Congress must disclose trades over $1,000 within 45 days under the STOCK Act. At least 25 disclosures name LLY — filed by 11 separate members or more and worth $116K–$565K combined (filings report bands, never exact amounts). 11 purchase-side, 14 sale-side, most recently on 2026-07-10.
| Member | Date | Action | Amount filed |
|---|---|---|---|
| 2026-07-10 | SELL | $1,001 - $15,000 | |
| 2026-06-10 | BUY | $50,001 - $100,000 | |
| 2026-04-14 | BUY | $1,001 - $15,000 |
Names withheld — plus 22 more records not shown.
See which membersEli Lilly is a buy because it maintains a healthy upward trend while staying comfortably within its established price range.
Don't guess. Practice this trade first.
Buy it with virtual cash and watch how it plays out — before a dollar of your own is on the line.
Practice LLY risk-free in your paper portfolioPaper trading, the AI Read & live indicators are inside a Money GPS membership — one price, the whole platform.
Beginner questions about LLY
Should I buy LLY stock?+
Based on the trend remaining above the 200-day average of $1051.09, we view this as a buy.
Is LLY a good long-term investment?+
The stock has shown growth within a 52-week range of $712.05 to $1249.45, suggesting long-term potential.
Is LLY a buy or a sell?+
Our analysis results in a buy call, supported by the price sitting above the 50-day average of $1168.36.
Is LLY overvalued?+
With a P/E ratio of 25.5 and an RSI of 54.4, the stock is currently priced in a neutral range.
Is LLY a good stock for beginners?+
It is a large company with a clear trend, though beginners should note the 52-week high of $1249.45.
Important disclaimer
This page is for educational and informational purposes only and is not financial, investment, tax, or legal advice, nor a recommendation, offer, or solicitation to buy, sell, or hold Eli Lilly (LLY) or any other security. The Money GPS is not a registered investment adviser, broker-dealer, or financial planner, and no content here should be relied upon to make an investment decision.
The verdict, indicators, and commentary are generated automatically — in part using AI — from third-party market data (via Yahoo Finance) that may be delayed, incomplete, or inaccurate, and is provided “as is” without any warranty. Figures reflect the market as of 2026-08-07 and change constantly; the read above may already be out of date. A “Buy,” “Hold,” or “Be Careful” label is a simplified, rules-based signal for beginners — not a price target or a guarantee of any outcome.
All investing involves risk, including the possible loss of your entire principal. Past performance and historical patterns do not guarantee future results. Always do your own research and consult a licensed financial professional who knows your personal circumstances before investing. You are solely responsible for your own investment decisions. The Money GPS and its authors may hold positions in the securities discussed and accept no liability for any loss arising from the use of this information.